This is the authors' abstract. We don't add key points for this paper.
The effect of flexible versus conformationally constrained phosphonate internucleotide linkages on CpG-mediated TLR9 activation was investigated. Sixteen analogues of the CpG oligonucleotide ODN 2006, a well-known TLR9 agonist, uniformly modified at all CpG motifs, were synthesized and evaluated in a human TLR9 (hTLR9) reporter cell line and peripheral blood mononuclear cells. Analogues bearing conformationally constrained 2′,3′-cytidine phosphonate modifications (ODN1–ODN10) generally exhibited enhanced activity relative to ODN 2006, with ODN1 (incorporating modification I) displaying ∼30-fold increased potency. Analogues with flexible phosphonate linkages (ODN11, ODN13, ODN15, ODN16) showed comparable activity to that of the parent ODN, whereas additional sugar modification abolished activity (ODN12, ODN14). A hexamer (ODN-B) incorporating the most potent modification I, when combined with CpG DNA, enhanced hTLR9 activation, consistent with interaction at the auxiliary 5′-xCx site. This study evaluates phosphonate internucleotide linkages in CpG oligonucleotides and demonstrates that a conformationally constrained phosphonate backbone in ODN 2006 analogues enhances hTLR9 activation, offering a potential strategy for the development of potent immunostimulatory oligonucleotides.
No takes yet. Share an insight, caveat, or question.
Kóšiová et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: